Hearscape
← Therapeutics
Details checkedStrong evidenceCheckedtrial

AC102 by AudioCure Pharma

Also known as: AC102, AC102-201

AudioCure Pharma

Primary source
Company
AudioCure Pharma
Program Type
Therapeutic
Modality
Small Molecule
Stage
Phase 2
Status
Active
Target Gene
—
Route / Mode
Intratympanic injection
Confidence
91%
Status Confidence
Status confirmed
Evidence Strength
Strong evidence
Last Reviewed
2026-05-31
Geography
Europe
Population
adult, sudden, tinnitus
Trial IDs
1
Mechanism

Local gel-formulated small molecule is intended to protect sensory hair cells and restore inner-ear neural connections in sudden hearing loss.

Indications
Hearing LossSensorineural Hearing LossSudden Sensorineural Hearing LossTinnitus
Notes

A closely watched ISSNHL program with active Phase 2 development and a differentiated regenerative/neuroprotective positioning relative to steroid standard care.

Evidence & Sources
4 structured sources
company
Supports: canonicalName, aliases, company, mechanism, indications, route
IDs: AC102
Open
company
Supports: stage, status, geography, notes
IDs: AC102, AC102-201
Open
manual
Supports: trialIds, populationTags
IDs: NCT05776459
Open
publication
Supports: mechanism, notes
IDs: PMC11009624
Open
Key Events
2022-10-16
AudioCure initiated the Phase 2 AC102 study in sudden hearing loss
Clinical Trials (1)
NCT05776459
Related Programs
Otarmeni by Regeneron
Company: Regeneron Pharmaceuticals · Gene Therapy · Approved
PEDMARK by Fennec Pharmaceuticals
Company: Fennec Pharmaceuticals · Small Molecule · Marketed
AK-OTOF by Eli Lilly and Akouos
Company: Eli Lilly and Company · Gene Therapy · Phase 2
SENS-401 (Arazasetron) by Sensorion
Company: Sensorion · Small Molecule · Phase 2
SENS-501 by Sensorion
Company: Sensorion · Gene Therapy · Phase 1/2
Rincell-1 by Rinri Therapeutics
Company: Rinri Therapeutics · Cell Therapy · Phase 1/2